Singular Genomics Systems, Inc.

    Singular Genomics Systems, Inc.

    NNASDAQ:OMIC
    20.01
    USD
    0.00
    (0.00%)
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    TTM
    Revenue per Share
    - -
    - -
    - -
    0.32
    1.2
    1.07
    Basic EPS, GAAP
    -7.48
    -12.08
    -63.01
    -38.32
    -39.08
    -34.78
    Free Cash Flow per Basic Share
    -7.41
    -11.35
    -36.09
    -39.26
    -30.75
    -32.58
    Dividend per Share
    - -
    - -
    - -
    - -
    - -
    - -
    Book Value per Share
    -15.29
    -22.97
    -96.9
    -102.36
    -139.12
    -161.43
    Tangible Book Value per Share
    -15.01
    -22.29
    214.47
    109.77
    73.77
    49.66
    Basic Weighted Avg Shares
    2
    2
    2
    2
    2
    2
    Sales/Revenue/Turnover
    - -
    - -
    - -
    1
    3
    3
    Operating Margin (%)
    - -
    - -
    - -
    -12,220.52
    -3,531.47
    -3,488.52
    Depreciation Expense
    - -
    1
    1
    6
    7
    7
    Net Income, GAAP
    -12
    -28
    -99
    -91
    -95
    -86
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    - -
    - -
    Profit Margin (%)
    - -
    - -
    - -
    -11,879.61
    -3,257.3
    -3,237.88
    Working Capital
    45
    24
    341
    254
    174
    112
    LT Debt
    2
    8
    10
    53
    68
    45
    Total Equity
    -25
    -52
    336
    260
    179
    123
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)
    - -
    - -
    - -
    - -
    - -
    - -

    Capital Structure

    USD

    •

    in mil. unless spec.
    Mar'24
    Jun'24
    Sep'24
    ST Debt
    8
    7
    5
    LT Borrowings
    8
    6
    5
    LT Finance Leases
    58
    58
    40
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    2
    2
    3
    Market Capitalization
    38
    21
    39

    Working Capital

    USD

    •

    in mil. unless spec.
    Mar'24
    Jun'24
    Sep'24
    Total Current Assets
    166
    149
    130
    Cash, Cash Equivalents & STI
    151
    133
    114
    Accounts Receivable, Net
    - -
    - -
    - -
    Inventories
    13
    12
    12
    Total Current Liabilities
    16
    17
    18
    Payables & Accruals
    3
    2
    3
    ST Debt
    8
    7
    5
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    - -
    - -
    -31.24%
    Free Cash Flow
    - -
    - -
    -19.87%
    Net Income, GAAP
    - -
    - -
    4.34%
    Sales/Revenue/Turnover
    - -
    - -
    280.52%
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    - -
    - -
    - -
    1
    1
    2023
    1
    1
    - -
    1
    3
    2024
    - -
    1
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    -9.3
    -10.16
    -10.02
    -8.84
    -38.32
    2023
    -9.86
    -10.58
    -9.25
    - -
    -39.08
    2024
    -10.16
    -8.57
    -6.72
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    - -
    - -
    - -
    - -
    - -
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • globenewswire.com

      Singular Genomics Announces Closing of Acquisition by Deerfield Management

    • accessnewswire.com

      Investors With Losses Are Invited To Join The Schall Law Firm In An Investigation Into Singular Genomics Systems, Inc. For Securities Fraud

    • accessnewswire.com

      Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Shareholders With Losses To Reach Out

    • prnewswire.com

      OMIC Investors Have the Opportunity to Join Investigation of Singular Genomics Systems, Inc. with the Schall Law Firm

    • accessnewswire.com

      Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out

    • accessnewswire.com

      Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities Fraud

    • accessnewswire.com

      Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out

    • accessnewswire.com

      Investors With Losses Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities Fraud

    • accessnewswire.com

      Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out

    • accessnewswire.com

      Investors With Losses Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities Fraud

    • businesswire.com

      SINGULAR GENOMICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Singular Genomics Systems, Inc. - OMIC

    • accessnewswire.com

      Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out

    • accessnewswire.com

      Investors With Losses Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities Fraud

    • accessnewswire.com

      Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out

    • accessnewswire.com

      Investors With Losses Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities Fraud

    • accessnewswire.com

      Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out

    • businesswire.com

      OMIC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Singular Genomics Systems, Inc. Is Fair to Shareholders

    • businesswire.com

      SINGULAR GENOMICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Singular Genomics Systems, Inc. - OMIC

    • businesswire.com

      OMIC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Singular Genomics Systems, Inc. Is Fair to Shareholders

    • businesswire.com

      Shareholder Alert: Ademi LLP Investigates Whether Singular Genomics Systems, Inc. is Obtaining a Fair Price for Its Public Shareholders